Ingrezza Sprinkles for Huntington’s, Tivdak for Cervical Cancer, Xolremdi for WHIM, Esprit Stent for CLTI-BTK
Update: 2024-05-06
Description
Please visit Nascentmc.com for medical writing assistance for your company.
Visit learnAMAstyle.com for free downloads on medical writing and editing
Ingrezza for Huntington’s:
- The FDA has approved valbenazine (INGREZZA® SPRINKLE) capsules for adults with tardive dyskinesia and chorea associated with Huntington's disease.
- This new oral granules formulation provides an alternative for those with swallowing difficulties, maintaining the same dosage strengths as the original capsule form.
- Valbenazine is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor designed to reduce uncontrollable movements by inhibiting dopamine release.
Tivdak for Cervical Cancer:
- Tisotumab vedotin-tftv (TIVDAK) has been approved for recurrent or metastatic cervical cancer after chemotherapy failure.
- This approval was based on results from a Phase 3 trial showing a significant overall survival benefit compared to chemotherapy.
- The approval highlights a significant advancement in treating this aggressive form of cancer, granted to Pfizer and Genmab A/S.
Xolremdi for WHIM:
- Mavorixafor (Xolremdi) has been approved for WHIM syndrome in patients 12 years and older to increase circulating neutrophils and lymphocytes.
- WHIM syndrome is a rare genetic disorder impairing immune function, and mavorixafor significantly improves cell counts and reduces infection risk.
- Approval was based on positive results from a double-blind trial and granted to X4 Pharmaceuticals.
Esprit Stent for CLTI-BTK:
- The FDA has approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System for chronic limb-threatening ischemia below-the-knee.
- This is the first approval of its kind in the U.S., offering an alternative to traditional balloon angioplasty.
- The approval was based on positive outcomes from the LIFE-BTK trial, showing significant disease progression reduction compared to standard care, granted to Abbott Laboratories.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
